Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention

Cancer Prevention Research

Volumn 4, Issue 2, 2011, Pages 259-269

  Limburg, Paul J ^a   Mahoney, Michelle R ^a   Ziegler, Katie L Allen ^a   Sontag, Stephen J ^b   Schoen, Robert E ^c   Benya, Richard ^d   Lawson, Michael J ^e   Weinberg, David S ^f   Stoffel, Elena ^g   Chiorean, Michael ^h   Heigh, Russell ⁱ   Levine, Joel ^j   Della'Zanna, Gary ^k   Rodriguez, Luz ^k   Richmond, Ellen ^k   Gostout, Christopher ^a   Mandrekar, Sumithra J ^a   Smyrk, Thomas C ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b Hines Veteran's Administration   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e KAISER PERMANENTE MEDICAL CENTER   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF CONNECTICUT   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FRUCTOSE OLIGOSACCHARIDE; MALTODEXTRIN; ORAFTI; PREBIOTIC AGENT; SULINDAC; UNCLASSIFIED DRUG;

ABERRANT CRYPT FOCUS; ADULT; APOPTOSIS; ARTICLE; CHEMOPROPHYLAXIS; CHROMOENDOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DIETARY FIBER; FEMALE; HUMAN; HUMAN TISSUE; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

ABERRANT CRYPT FOCI; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DIETARY FIBER; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PYRROLES; SULINDAC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79551696016     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0215     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Herszenyi L, Farinati F, Miheller P, Tulassay Z. Chemoprevention of colorectal cancer: feasibility in everyday practice? Eur J Cancer Prev 2008;17:502-14.
3. Das D, Arber N, Jankowski JA. Chemoprevention of colorectal cancer. Digestion 2007;76:51-67. (Pubitemid 47608860)
4. Hawk ET, Umar A, Viner JL. Colorectal cancer chemoprevention - an overview of the science. Gastroenterology 2004;126:1423-47. (Pubitemid 38552806)
5. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6. (Pubitemid 23131373)
6. Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083-7.
7. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:9-11.
8. Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997;40:344-9. (Pubitemid 27145647)
9. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE. NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993;88:1652-6. (Pubitemid 23298112)
10. Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett 2008;260:11-9.
11. Singh H, Mahmud SM, Turner D, Xue L, Demers AA, Bernstein CN. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 2009;104:3015-23.
12. Yang YX, Hennessy S, Propert K, Hwang WT, Sarkar M, Lewis JD. Chronic statin therapy and the risk of colorectal cancer. Pharmaco-epidemiol Drug Saf 2008;17:869-76.
13. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007;133:393-402. (Pubitemid 47187349)
14. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006;98:69-72. (Pubitemid 43057094)
15. Pool-Zobel B, van Loo J, Rowland I, Roberfroid MB. Experimental evidences on the potential of prebiotic fructans to reduce the risk of colon cancer. Br J Nutr 2002;87 Suppl 2:S273-81.
16. Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr 2007;85:488-96. (Pubitemid 46220953)
17. Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, et al. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res 2008;1:21-31.
18. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 2005;41:1911-22. (Pubitemid 41557677)
19. Stevens RG, Swede H, Rosenberg DW. Epidemiology of colonic aberrant crypt foci: review and analysis of existing studies. Cancer Lett 2007;252:171-83. (Pubitemid 46809786)
20. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-84. (Pubitemid 28496193)
21. Wong Kee Song LM, Adler DG, Chand B, Conway JD, Croffie JM, Disario JA, et al. Chromoendoscopy. Gastrointest Endosc 2007;66:639-49. (Pubitemid 47464263)
22. Pocock SL, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
23. Lance P, Hamilton SR. Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention. Cancer Prev Res 2008;1:4-8.
24. Gupta AK, Schoen RE. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans? Curr Opin Gastroenterol 2009;25:59-65.
25. Gupta AK, Pretlow TP, Schoen RE. Aberrant crypt foci: what we know and what we need to know. Clin Gastroenterol Hepatol 2007;5:526-33. (Pubitemid 46660772)
26. Hurlstone DP, Karajeh M, Sanders DS, Drew SK, Cross SS. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia. Am J Gastroenterol 2005;100:1283-9. (Pubitemid 40904350)
27. Rudolph RE, Dominitz JA, Lampe JW, Levy L, Qu P, Li SS, et al. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 2005;14:605-8. (Pubitemid 40489202)
28. Seike K, Koda K, Oda K, Kosugi C, Shimizu K, Nishimura M, et al. Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am J Gastroenterol 2006;101:1362-9. (Pubitemid 43830006)
29. Stevens RG, Swede H, Heinen CD, Jablonski M, Grupka M, Ross B, et al. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett 2007;248:262-8. (Pubitemid 46343762)
30. Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Seligson D, et al. A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol 2009;7:568-74.
31. Schoen RE, Mutch M, Rall C, Dry SM, Seligson D, Umar A, et al. The natural history of aberrant crypt foci. Gastrointest Endosc 2008;67:1097-102. (Pubitemid 351728109)
32. Pinsky PF, Fleshman J, Mutch M, Rall C, Charabaty A, Seligson D, et al. One year recurrence of aberrant crypt foci. Cancer Prev Res 3:839-43.
33. Gupta AK, Pinsky P, Rall C, Mutch M, Dry S, Seligson D, et al. Reliability and accuracy of the endoscopic appearance in the identification of aberrant crypt foci. Gastrointest Endosc 2009;70:322-30.
34. Hisamuddin IM, Wehbi MA, Schmotzer B, Easley KA, Hylind LM, Giardiello FM, et al. Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2005;14:2366-9. (Pubitemid 41437838)
35. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007;25:3462-8. (Pubitemid 47310884)
36. Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res 3:588-96.
37. Rowland IR, Rumney CJ, Coutts JT, Lievense LC. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 1998;19:281-5. (Pubitemid 28375422)